B6-hPDL1-V Mouse
Product Name
B6-hPDL1-V Mouse
Product ID
C001420
Strain Name
C57BL/6NCya-Cd274em1(hCD274 IgV-like)/Cya
Backgroud
C57BL/6NCya
When using this mouse strain in a publication, please cite “B6-hPDL1-V Mouse (Catalog C001420) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Gene Name
Gene Alias
B7-H, B7H1, PDL1, PD-L1, hPD-L1, PDCD1L1, PDCD1LG1
NCBI ID
Chromosome
Chr 9
MGI ID
Datasheet
Strain Description
Programmed cell death 1 ligand 1 (PD-L1), also known as cluster of differentiation 274 (CD274) or B7 homolog 1 (B7H1), is an immune inhibitory receptor ligand. PD-L1 is a type I transmembrane protein with immunoglobulin V-like (IgV) and C-like (IgC) structural domains and is expressed by hematopoietic and non-hematopoietic cells, including T cells, B cells, and various types of tumor cells [1]. PD-L1 can bind to PD-1 on the surface of CD8+ T cells, inhibiting the activity of CD8+ T cells. This interaction can prevent the immune system from damaging normal tissues, but it can also be used by tumor cells to escape immune surveillance. Monoclonal antibodies that competitively bind to PD-L1 can relieve the immune function inhibition mediated by the binding of PD-1 and PD-L1. This can reactivate CD8+ T cells, triggering the human body's anti-tumor immune response [2]. Therefore, the development of antibody drugs targeting PD-1 and PD-L1 is a hot area in tumor immunotherapy.
This strain is a humanized model of the mouse Pdl1 gene in which the gene sequence encoding the extracellular domain (immunoglobulin V-like, IgV-like) of mouse PD-L1 protein is replaced with the corresponding human PD-L1 gene sequence. B6-hPDL1-V mice can be used for the research of PD-L1 targeted drug development screening, efficacy and safety evaluation, tumor immunotherapy evaluation, and immune system mechanisms [2-4].
Reference
Kornepati AVR, Vadlamudi RK, Curiel TJ. Programmed death ligand 1 signals in cancer cells. Nat Rev Cancer. 2022 Mar;22(3):174-189.
Escors D, Gato-Cañas M, Zuazo M, Arasanz H, García-Granda MJ, Vera R, Kochan G. The intracellular signalosome of PD-L1 in cancer cells. Signal Transduct Target Ther. 2018 Sep 28;3:26.
Huang CY, Wang Y, Luo GY, Han F, Li YQ, Zhou ZG, Xu GL. Relationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular Carcinoma. J Immunother. 2017 Nov/Dec;40(9):323-333.
Zhang C, Wu S, Xue X, Li M, Qin X, Li W, Han W, Zhang Y. Anti-tumor immunotherapy by blockade of the PD-1/PD-L1 pathway with recombinant human PD-1-IgV. Cytotherapy. 2008;10(7):711-9.
Strain Strategy
The gene sequence encoding the extracellular domain (immunoglobulin V-like, IgV-like) of the mouse PD-L1 protein is replaced with the corresponding human PD-L1 gene sequence, while the sequence encoding the signal peptide is retained.
Figure 1. Gene editing strategy for B6-hPDL1-V mice.
Application Area
Development and screening of PD-L1-targeted drugs;
Efficacy and safety evaluation of PD-L1-targeted drugs;
Evaluation of tumor immunotherapy;
Research on the immune system and tumor immune escape mechanisms.
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.